Latest filings (excl ownership)
15-12B
Securities registration termination
3 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
8-K
Completion of Acquisition or Disposition of Assets
23 Apr 19
25-NSE
Exchange delisting
23 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
17 Apr 19
425
Business combination disclosure
17 Apr 19
DEFM14A
Proxy related to merger
20 Mar 19
425
Business combination disclosure
15 Mar 19
8-K
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights
15 Mar 19
425
Business combination disclosure
15 Mar 19
425
Business combination disclosure
12 Mar 19
10-K
2018 FY
Annual report
7 Mar 19
8-K
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results
7 Mar 19
425
Business combination disclosure
22 Feb 19
425
Business combination disclosure
15 Feb 19
425
Business combination disclosure
12 Feb 19
425
Business combination disclosure
11 Feb 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Jan 19
425
Business combination disclosure
7 Jan 19
425
Business combination disclosure
11 Dec 18
425
Business combination disclosure
6 Dec 18
425
Business combination disclosure
6 Dec 18
425
Business combination disclosure
6 Dec 18
425
Business combination disclosure
6 Dec 18
8-K
To be effected by anall-stock transaction plus issuance of Contingent Value Rights (“CVRs”); completion expected H1 2019
6 Dec 18
425
Business combination disclosure
6 Dec 18
10-Q
2018 Q3
Quarterly report
1 Nov 18
8-K
OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
1 Nov 18
8-K
Other Events
17 Oct 18
8-K
Departure of Directors or Certain Officers
1 Oct 18
8-K
OncoMed Provides Update on Navicixizumab Partnership
20 Sep 18
CT ORDER
Confidential treatment order
21 Aug 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
8-K
OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights
2 Aug 18
8-K/A
Departure of Directors or Certain Officers
27 Jun 18
Latest ownership filings
SC 13D/A
OncoMed Pharmaceuticals Inc
26 Apr 19
4
Alicia J. Hager
23 Apr 19
4
JONATHAN D ROOT
23 Apr 19
4
JACK W LASERSOHN
23 Apr 19
4
John A. Lewicki
23 Apr 19
4
DEEPIKA PAKIANATHAN
23 Apr 19
4
Yvonne Li
23 Apr 19
4
Robert Stagg
23 Apr 19
4
PERRY A KARSEN
23 Apr 19
SC 13D
OncoMed Pharmaceuticals Inc
15 Mar 19
SC 13G/A
OncoMed Pharmaceuticals Inc
14 Feb 19
SC 13G
OncoMed Pharmaceuticals Inc
14 Feb 19
SC 13G/A
OncoMed Pharmaceuticals Inc
14 Feb 19
5
Yvonne Li
13 Feb 19
5
John A. Lewicki
13 Feb 19
SC 13G/A
OncoMed Pharmaceuticals Inc
13 Feb 19
SC 13G/A
OncoMed Pharmaceuticals Inc
12 Feb 19
SC 13G/A
OncoMed Pharmaceuticals Inc
8 Feb 19
4
Austin Gurney
26 Dec 18
SC 13G
OncoMed Pharmaceuticals Inc
21 Dec 18
SC 13D
OncoMed Pharmaceuticals Inc
17 Dec 18
4
Robert Stagg
11 Oct 18
4
Yvonne Li
11 Oct 18
4
Austin Gurney
11 Oct 18
4
Alicia J. Hager
11 Oct 18
4
John A. Lewicki
11 Oct 18
4
Yvonne Li
10 Oct 18
4
Austin Gurney
10 Oct 18
4
Robert Stagg
10 Oct 18
4
John A. Lewicki
10 Oct 18
4
Alicia J. Hager
10 Oct 18
4
MICHAEL S WYZGA
25 Jun 18
4
DEEPIKA PAKIANATHAN
25 Jun 18
4
Denise Pollard-Knight
25 Jun 18
4
PERRY A KARSEN
25 Jun 18
4
JACK W LASERSOHN
25 Jun 18
4
JONATHAN D ROOT
25 Jun 18
4
Rick E Winningham
25 Jun 18
4
Yvonne Li
26 Apr 18
4
Robert Stagg
26 Apr 18